Systematic review of controlled clinical studies using umbilical cord blood for regenerative therapy: Identifying barriers to assessing efficacy

Aziz, Joseph; Liao, Gary; Adams, Zach; Rizk, Mina; Shorr, Risa; Allan, David S.

doi:10.1016/j.jcyt.2019.08.004

Cited by 15 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Autogenous stem cell transplant is not the gold standard in any of the above-mentioned indications. A systematic review from 2019 [16], which collected controlled clinical studies from June 1, 2016 to April 1, 2018, investigated the use of stem cells in regenerative medicine. These authors identified four controlled studies treating cerebral palsy (CP), of which autogenic transplants were used in only one [17].…”

Section: Discussionmentioning

confidence: 99%

“…The study reported an improvement in motor function (GMFM-66) in children with CP one year after the use of allogeneic stem cell transplantation at a dose of ≥ 2x10 7 /kg [17]. The authors of the review [16] found three additional studies assessing the usefulness of stem cell transplantation for children with type 1 diabetes, two of which included autogenous transplants. In the study, the authors did not report statistically significant differences in the main outcomes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Collection of umbilical cord blood and the risk of complications in postpartum women after natural labour in the context of the possibility of umbilical cord stem cells usage in clinical practice

et al. 2021

View full text Add to dashboard Cite

Objectives: Comparison of changes in peripheral blood venous morphology and the frequency of select complications in patients who underwent umbilical cord blood collection during the third stage of labour by in the utero method compared to patients who did not undergo this procedure. Presentation of current therapeutic possibilities of cord blood stem cells. Material and methods: The study involved 248 patients who had a vaginal delivery and had umbilical cord blood taken by in utero method during the third stage of labour. The control group consisted of the first 400 patients who gave vaginal delivery starting in 2019. Each patient had a venous peripheral blood count taken before delivery and 18 hours after delivery. Changes in the results of laboratory tests and the occurrence of adverse outcomes, such as postpartum curettage, postpartum haemorrhage and manual removal of placenta, in the 3 rd and 4 th stage delivery periods, were analysed. Results: In the blood donor group there were significantly lower haemoglobin (11.32 g/L vs 11.61 g/L, p = 0.004) and haematocrit (32.83% vs 33.82% p = 0.001) concentrations after delivery. Umbilical cord donors had a greater difference in haemoglobin (postpartum minus prepartum) (-1.4 g/L vs-0.9 g/L, p = 000), and haematocrit (-4.05% vs-2.5% , p = 0.000). The study group had a higher percentage of patients with postpartum anaemia (haemoglobin concentration < 10 g/L) (15.9% vs 10.64%, p = 0.05), but the result were borderline significant. The groups did not differ in terms of the percentage of postpartum curettage, PPH, manual removal of placenta, percentage of severe anaemia (Hb < 7g/L) or transfusion requirement. Conclusion: Collection of umbilical cord blood during the 3 rd stage of labour using the in utero method is associated with a statistically significant increase of blood loss and a higher probability of postpartum anaemia. The observed changes are minor and may have little clinical significance in otherwise healthy patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Collection of umbilical cord blood and the risk of complications in postpartum women after natural labour in the context of the possibility of umbilical cord stem cells usage in clinical practice

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Studies on biosafety and bioefficacy of stem cells h ave been carried out for many years. There have been few reports addressing the biosafety and bioefficacy profiles of stem cells [10,40,41], which showed the importance of addressing these issues. As of now, there is no standard or conclusive data that can be used to establish a proper protocol for biosafety and bioefficacy assessment.…”

Section: About Here]mentioning

confidence: 99%

Machine Learning in Stem Cells Research: Application for Biosafety and Bioefficacy Assessment

et al. 2021

View full text Add to dashboard Cite

The applicability of machine learning-based analysis in the field of biomedical field has been very beneficial in determining the biological mechanism and validation for a wide range of biological scenarios. This approach is also gaining momentum in variou s stem cells research activities, specifically for stem cells characterization and differentiation pattern. The adoption of similar computational approaches to study and assess biosafety and bioefficacy risks of stem cells for clinical application is the n ext progression. In particular where tumorigenicity has been one of the major concerns in stem cells therapy. There are many factors influencing tumorigenicity in stem cells which may be difficult to capture under conventional laboratory settings. In addition, given the possible multifactorial etiology of tumorigenicity, defining a onesize-fits-all strategy to test such risk in stem cells might not be feasible and may compromise stem cells safety and effectiveness in therapy. Given the increase in biological datasets (which is no longer limited to genomic data) and the advancement of health informatics powered by state-of-the-art machine learning algorithms, there exists a potential for practical application in biosafety and bioefficacy of stem cells therap y. Here, we identified relevant machine learning approaches and suggested protocols intended for stem cells research focusing on the possibility of its usage for stem cells biosafety and bioefficacy assessment. Ultimately, generating models that may assist healthcare professionals to make a better-informed decision in stem cell therapy.

show abstract

“…Mesenchymal Stromal Cells (MSCs) are a multipotent progenitor cells that have been largely used for multiple clinical applications, including autoimmune and inflammatory diseases, allotransplant rejection, spinal cord injuries, myocardial infarction, degenerative disorders, bone diseases, severe pneumonia, extensive burns and severe chronic wounds [ 1 – 4 ]. Nowadays, these cells are even more in demand for pre-clinical and clinical trials since emerging viral infections are severely affecting people’s health around the world [ 5 ].…”

Section: Biological Properties Of Mscsmentioning

confidence: 99%

Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19

Rocha

Oliveira

Noronha

et al. 2020

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) constitute a heterogeneous population of stromal cells with immunomodulatory and regenerative properties that support their therapeutic use. MSCs isolated from many tissue sources replicate vigorously in vitro and maintain their main biological properties allowing their widespread clinical application. To date, most MSC-based preclinical and clinical trials targeted immune-mediated and inflammatory diseases. Nevertheless, MSCs have antiviral properties and have been used in the treatment of various viral infections in the last years. Here, we revised in detail the biological properties of MSCs and their preclinical and clinical applications in viral diseases, including the disease caused by the severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2) infection (COVID-19). Notably, rapidly increasing numbers of MSC-based therapies for COVID-19 have recently been reported. MSCs are theoretically capable of reducing inflammation and promote lung regeneration in severe COVID-19 patients. We critically discuss the rationale, advantages and disadvantages of MSC-based therapies for viral infections and also specifically for COVID-19 and point out some directions in this field. Finally, we argue that MSC-based therapy may be a promising therapeutic strategy for severe COVID-19 and other emergent respiratory tract viral infections, beyond the viral infection diseases in which MSCs have already been clinically applied.

show abstract

Systematic review of controlled clinical studies using umbilical cord blood for regenerative therapy: Identifying barriers to assessing efficacy

Cited by 15 publications

References 18 publications

Collection of umbilical cord blood and the risk of complications in postpartum women after natural labour in the context of the possibility of umbilical cord stem cells usage in clinical practice

Collection of umbilical cord blood and the risk of complications in postpartum women after natural labour in the context of the possibility of umbilical cord stem cells usage in clinical practice

Machine Learning in Stem Cells Research: Application for Biosafety and Bioefficacy Assessment

Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19

Contact Info

Product

Resources

About